Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study

Hiroyasu Yamashiro,Masataka Sawaki,Norikazu Masuda,Yasuhiro Okumura,Toshimi Takano,Eriko Tokunaga,Tsuyoshi Saito,Yasuaki Sagara,Kosuke Yamazaki,Yoshihiro Kawaguchi,Tecchuu Lee,Shinji Ozaki,Kazuhiko Yamagami,Naoki Yamamoto,Katsumasa Kuroi,Hirofumi Suwa,Shoichiro Ohtani,Toshikazu Ito,Shinji Yasuno,Satoshi Morita,Shinji Ohno,Masakazu Toi

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study

2018

Background:There are little data on the usefulness of trastuzumab (TZM) retreatment as the first-line treatment for patients with HER2 (human epidermal growth factor receptor 2)–positive breast can...

Keywords:

neo adjuvant
Observational study
Breast cancer
Oncology
Internal medicine
Medicine
Trastuzumab
multidrug chemotherapy
cytotoxic chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations